Lupus patients continue treatment in Follow-Up study
NCT ID NCT06875960
Summary
This study allows patients with lupus who completed two previous trials to continue taking the medication deucravacitinib. The goal is to maintain disease control for those who benefited from the drug. Only 35 participants who finished the earlier studies are eligible to join.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Local Institution - 0001
WITHDRAWNFarmington, Connecticut, 06030, United States
-
Local Institution - 0003
WITHDRAWNJackson, Tennessee, 38305, United States
-
New York University School Of Medicine
RECRUITINGNew York, New York, 10155, United States
Contact Phone: •••-•••-••••
-
Oklahoma Medical Research Foundation
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.